Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial

Japanese Patients ◽

Methotrexate Therapy

AB0400 Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: 2-Year Results of A Phase 3 TRIAL of Intravenous Golimumab

10.1136/annrheumdis-2014-eular.2049 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 939.1-939

Author(s):

M.E. Weinblatt ◽

C.O. Bingham ◽

A.M. Mendelsohn ◽

L. Kim ◽

K.H. Lo ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Efficacy ◽

Methotrexate Therapy ◽

Efficacy And Safety ◽

Phase 3

THU0218 Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase 3 Trial

10.1136/annrheumdis-2013-eular.746 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A238.2-A238

Author(s):

M. Weinblatt ◽

C. O. Bingham ◽

A. Mendelsohn ◽

L. Noonan ◽

S. Sheng ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Efficacy ◽

Methotrexate Therapy ◽

Efficacy And Safety ◽

Phase 3

Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study

The Journal of Rheumatology ◽

10.3899/jrheum.150613.c1 ◽

2016 ◽

Vol 43 (5) ◽

pp. 998-998

Keyword(s):

Rheumatoid Arthritis ◽

Japanese Patients ◽

Methotrexate Therapy ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind

Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120

Modern Rheumatology ◽

10.1080/14397595.2017.1404731 ◽

2017 ◽

Vol 28 (5) ◽

pp. 770-779 ◽

Cited By ~ 1

Author(s):

Tsutomu Takeuchi ◽

Masayoshi Harigai ◽

Yoshiya Tanaka ◽

Hisashi Yamanaka ◽

Naoki Ishiguro ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Efficacy ◽

Japanese Patients ◽

Disease Modifying Antirheumatic Drugs ◽

Antirheumatic Drugs ◽

Prior Therapy ◽

Disease Modifying

Faculty Opinions recommendation of Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718325310.793492804 ◽

2014 ◽

Author(s):

Ronald van Vollenhoven

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Alpha ◽

Methotrexate Therapy ◽

Human Antibody ◽

Necrosis Factor Alpha ◽

Subcutaneous Injections ◽

Factor Alpha ◽

Necrosis Factor

THU0199 Week 12 Clinical Response to Certolizumab Pegol Predicts Long-Term Outcomes Regardless of Concomitant Medications and Baseline Disease Characteristics in Japanese Patients with Active Rheumatoid Arthritis

10.1136/annrheumdis-2013-eular.727 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A231.1-A231

Author(s):

H. Yamanaka ◽

K. Yamamoto ◽

T. Takeuchi ◽

N. Ishiguro ◽

Y. Tanaka ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Response ◽

Certolizumab Pegol ◽

Japanese Patients ◽

Long Term Outcomes ◽

Disease Characteristics ◽

Concomitant Medications

THU0609 Patient-Reported Outcomes from A Phase 3 Study of Baricitinib versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis and An Inadequate Response To Background Methotrexate Therapy: Table 1.

10.1136/annrheumdis-2016-eular.1239 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 412.2-413 ◽

Cited By ~ 1

Author(s):

E. Keystone ◽

P. Taylor ◽

Y. Tanaka ◽

C. Gaich ◽

A.M. DeLozier ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Patient Reported Outcomes ◽

Methotrexate Therapy ◽

Inadequate Response ◽

Phase 3 ◽

Patient Reported

The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy

Arthritis & Rheumatism ◽

10.1002/art.30263 ◽

2011 ◽

Vol 63 (5) ◽

pp. 1200-1210 ◽

Cited By ~ 83

Author(s):

Paul Emery ◽

Roy Fleischmann ◽

Désirée van der Heijde ◽

Edward C. Keystone ◽

Mark C. Genovese ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Randomized Controlled ◽

Randomized Controlled Studies

Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy

International Journal of Rheumatic Diseases ◽

10.1111/1756-185x.12723 ◽

2015 ◽

Vol 19 (11) ◽

pp. 1143-1156 ◽

Cited By ~ 3

Author(s):

Zhanguo Li ◽

Fengchun Zhang ◽

Jonathan Kay ◽

Kaiyin Fei ◽

Chenglong Han ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Controlled Trial ◽

Methotrexate Therapy ◽

Chinese Patients ◽

Efficacy And Safety ◽

Phase 3

Concurrent Oral 1 - Rheumatoid Arthritis: Treatment [OP4-OP9]: OP4. Inhibition of Radiographic Progression and Improvements in Physical Function at 2 Years, with Increasing Clinical Efficacy Over Time, in Rheumatoid Arthritis (Ra) Patients Treated with Tocilizumab (Tcz): The Lithe Study

Rheumatology ◽

10.1093/rheumatology/keq701 ◽

2010 ◽

Vol 49 (Supplement 1) ◽

pp. i3-i5

Author(s):

R. Fleischmann ◽

R. Burgos-Vargas ◽

P. Ambs ◽

E. Alecock ◽

J. Kremer ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Physical Function ◽

Clinical Efficacy ◽

Rheumatoid Arthritis Treatment ◽

Over Time